Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plonmarlimab for rheumato-immune disease-associated HLH/MAS (Phase 2, single-arm)
ChiCTR2500107345Phase 2Completed
- Sponsor
- Beijing Friendship Hospital
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of plonmarlimab in haemophagocytic lymphohistiocytosis (HLH), macrophage activation syndrome (MAS), systemic juvenile idiopathic arthritis (SJIA) and 3 more, sponsored by Beijing Friendship Hospital. Primary endpoints: Stage 1 safety endpoint and Stage 2 overall response rate (ORR). Started Aug 2025; status: completed.
02
Drugs
plonmarlimab
03
Conditions
haemophagocytic lymphohistiocytosis (HLH)macrophage activation syndrome (MAS)systemic juvenile idiopathic arthritis (SJIA)adult-onset Still's disease (AOSD)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on ChiCTR2500107345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107345.